Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
Posted on: Thursday, 4 June 2009, 18:50 CDT
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue SVP, CFO Cadence Pharmaceuticals, Inc. 858-436-1400SOURCE Cadence Pharmaceuticals, Inc.
Source: PR Newswire
Related Articles
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
- Cadence Pharmaceuticals to Webcast October 7th Analyst Day
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2009 Financial Results on August 5, 2009
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
- Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
- Cadence Pharmaceuticals Announces Agreement With FDA on Increased Enrollment In Phase III Clinical Trial of Omigard(TM)
- Cadence Pharmaceuticals Announces Plan to Increase Number of Patients to Be Enrolled in Its Phase III Clinical Trial of Omigard(TM)
User Comments (0)

RSS Feeds